Lupin's partner Sandoz launched Ranluspec, its biosimilar ranibizumab, across Europe excluding Germany.
Company news · 12 Nov 2026 · Lupin (LUPIN)
The European Commission approved the drug in February 2026 for retinal diseases including wet AMD; no sales figures were given.
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.